Clinical evaluation of ulinastatin in the treatment of sepsis complicated with acute respiratory distress syndrome
LEI Wenlu
LI Yahui
ZHANG Dandan
Abstract：Objective To explore the clinical efficacy and safety of ulinastatin in the treatment of sepsis com-plicated with acute respiratory distress syndrome(ARDS).Methods A total of 92 patients with sepsis complicated with ARDS admitted to Department of Intensive Care Medicine of the Second Affiliated Hospital of Zhengzhou Universi-ty from June 2023 to June 2025 were retrospectively enrolled in this study. The patients were divided into the ulinasta-tin group(52 cases,received ulinastatin plus standard therapy)and the conventional treatment group(40 cases,received standard treatment alone)based on treatment regimen.The cure rate,28-day survival rate,inflammatory markers,severity scores and incidence of adverse reactions between the two groups were compared.Results The cure rate of the ulinasta-tin group was higher than that in the conventional treatment group(92.31%(48/52)vs 77.50%(31/40))(χ2=4.086,P<0.05).The 28-day cumulative survival rate in the ulinastatin group(94.23%(49/52))was also significantly higher than 80.0%(32/40)in the conventional treatment group(χ2=4.349,P<0.05).Kaplan-Meier analysis confirmed a statistically signifi-cant difference in the 28-day survival curves between the two groups(χ2=4.519,P<0.05).With the day of discharge from the intensive care unit as the evaluation time point,the white blood cell count,C-reactive protein,procalcitonin,and inter-leukin-6 in the ulinastatin group were lower than those in the conventional treatment group((6.53±0.99)ng/mL vs(10.85±1.35)ng/mL,(51.24±4.27)mg/L vs(81.45±2.94)mg/L,(4.75±1.05)μg/L vs(7.31±1.33)μg/L,(7.15±1.39)ng/L vs(10.45±1.56)ng/L),with statistically significant differences(t=17.717,40.151,10.320,10.703,all P<0.05).The Acute Physiology and Chronic Health EvaluationⅡand Sequential Organ Failure Assessment score in the ulinastatin group were lower than those in the conventional treatment group((12.45±3.47)points vs(18.33±3.31)points,(4.15±1.06)points vs(6.32±1.12)points),with statis-tically significant differences(t=8.219,9.428,both P<0.05).The incidence of adverse reactions showed no statistically signifi-cant difference between the ulinastatin group and the conventional treatment group(11.54%(6/52)vs 17.50%(7/40))(χ2=0.662,P>0.05).Conclusion Ulinastatin is clinically effective and safe in the treatment of sepsis complicated with ARDS.
Keywords：ulinastatinsepsisacute respiratory distress syndromeclinical efficacyadverse reaction
Publication Date：2025-11-25
Online Publishing Date：2025-12-04(First online date of this platform, not the publication date of the document)
Pages：5( 1340-1344 )